ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials.

ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials.

Bibliographic Details
Main Authors: Collins, R, Peto, R, Parish, S, Sleight, P
Format: Journal article
Language:English
Published: 1993

Similar Items